<bill session="109" type="s" number="1698" updated="2013-07-19T20:28:19-04:00">
  <state datetime="2005-09-14">REFERRED</state>
  <status>
    <introduced datetime="2005-09-14"/>
  </status>
  <introduced datetime="2005-09-14"/>
  <titles>
    <title as="introduced" type="short">Vaccines for the New Millennium Act of 2005</title>
    <title as="introduced" type="official">A bill to accelerate efforts to develop vaccines for diseases primarily affecting developing countries, and for other purposes.</title>
  </titles>
  <sponsor id="300060"/>
  <cosponsors>
    <cosponsor id="300008" joined="2005-10-17"/>
    <cosponsor id="300018" joined="2006-05-12"/>
    <cosponsor id="300038" joined="2005-12-12"/>
    <cosponsor id="300070" joined="2005-09-14"/>
    <cosponsor id="300076" joined="2006-05-09"/>
    <cosponsor id="400619" joined="2006-02-02"/>
  </cosponsors>
  <actions>
    <action datetime="2005-09-14">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S10039-10040"/>
    </action>
    <action state="REFERRED" datetime="2005-09-14">
      <text>Read twice and referred to the Committee on Finance.</text>
      <reference ref="CR S10040-10043" label="text of measure as introduced"/>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" activity="Referral, In Committee"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="109" type="h" number="3781"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="AIDS (Disease)"/>
    <term name="Child health"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Communicable diseases"/>
    <term name="Competition"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Contracts"/>
    <term name="Corporation taxes"/>
    <term name="Developing countries"/>
    <term name="Development credit institutions"/>
    <term name="Dispute settlement"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Economics and public finance"/>
    <term name="Families"/>
    <term name="Foreign trade and international finance"/>
    <term name="Gifts"/>
    <term name="Government contractors"/>
    <term name="Government operations and politics"/>
    <term name="Government procurement"/>
    <term name="Government trust funds"/>
    <term name="Governmental investigations"/>
    <term name="Human immunodeficiency viruses"/>
    <term name="Income tax"/>
    <term name="Intellectual property"/>
    <term name="International affairs"/>
    <term name="International agencies"/>
    <term name="International cooperation in science"/>
    <term name="Law"/>
    <term name="Liability (Law)"/>
    <term name="Malaria"/>
    <term name="Medical malpractice"/>
    <term name="Medical technology"/>
    <term name="Negotiations"/>
    <term name="Nongovernmental organizations"/>
    <term name="Nonprofit organizations"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Preventive medicine"/>
    <term name="Prices"/>
    <term name="Public-private partnerships"/>
    <term name="Research and development"/>
    <term name="Research and development tax credit"/>
    <term name="Research grants"/>
    <term name="Science, technology, communications"/>
    <term name="Small business"/>
    <term name="Social welfare"/>
    <term name="Tax credits"/>
    <term name="Tax refunds"/>
    <term name="Taxation"/>
    <term name="Technology transfer"/>
    <term name="Treaties"/>
    <term name="Tuberculosis"/>
    <term name="United Nations"/>
    <term name="Vaccination"/>
    <term name="Vaccines"/>
    <term name="World health"/>
  </subjects>
  <amendments/>
  <summary>9/14/2005--Introduced.
Vaccines for the New Millennium Act of 2005 - Directs the President to establish a strategy to accelerate efforts to develop vaccines and microbicides for neglected diseases such as HIV/AIDS, malaria, and tuberculosis, which shall: (1) expand public-private partnerships; (2) create economic incentives for such vaccines' research, development, and manufacturing; (3) include the negotiation of advanced market commitments; (4) address related intellectual property and regulatory approval issues; (5) maximize U.S. capabilities to support clinical trials in developing countries; (6) expand the purchase and delivery of existing vaccines; and (7) address the challenges of advance delivery of vaccines in developing countries. Directs the Secretary of the Treasury to: (1) enter into negotiations with the World Bank, the International Development Association, Global Alliance for Vaccines and Immunizations, and other interested parties to establish advanced market commitments to purchase such vaccines and microbicides; and (2) establish in the Treasury the Lifesaving Vaccine Purchase Fund. Amends the Internal Revenue Code to establish business credits for: (1) vaccine research related to HIV/AIDS, malaria, tuberculosis, or certain infectious diseases afflicting developing countries; and (2) certain sales of lifesaving vaccines to nonprofit organizations, or to foreign governments or instrumentalities for distribution in developing countries. Amends the Small Business Act to: (1) direct the Small Business Administration (SBA) to establish a four-year pilot program to encourage the development of such vaccines and microbicides, including program outreach activities; and (2) provide Small Business Innovation Research Program (SBIR) and Small Business Technology Transfer Program (STTR) funding for such vaccines and microbicides.</summary>
</bill>
